N/A N=61 Enhancing Parenting for Depressed Caregivers
Depression
Primary: Feasibility of a Parent Coaching Intervention — 6; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=17 Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy
Focal Epilepsy
Primary: Intensity of the MRI Signal in the Left Temporal Precentral Zone — 1.06; 1.04 ratio
Phase 1 N=28 E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)
Non-small-cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) — 4 mg BID
Phase 4 N=100 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)
Parkinson's Disease · Essential Tremor · Dystonia
Primary: Identify the Rate of User-related Battery Depletion Adverse Events Per Subject-month Requiring Intervention by a Health Care Professional (HCP) and/or the HCP's…
N/A N=63 E-Mental Health Adolescent Depression Program (LEAP)
Depression
Primary: Children's Depression Rating Scale Revised (CDRS-R) — 57.18; 61.67; 44.94; 58.93 units on a scale
Phase 3 N=42 Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
Hypoparathyroidism
Primary: Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 8, Based on Investigator Prescribed Data. — 21.1; 26.1 percentage of participants — p=>0.999
Phase 2 N=60 Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants
Meningococcal Disease
Primary: Percentage of Subjects With Bactericidal Titers ≥1:4 Against Meningococcal Strains One Month After Second and Third Vaccination of rMenB Vaccine With and Without OMV-NZ…
Phase 1 N=9 A Study of E7080 in Subjects With Solid Tumor
Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0 Participants
Phase 2 N=23 Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer
Primary: PSA Response — 0 participants
Phase 3 N=87 Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults
Opioid Dependence
Primary: Change of Opioid Use From Week 1 to 13 — 0.00; 0.27; 0.39 Mean Proportion of Opioid Use in Week 13 — p==0.00874
Phase 1 N=27 An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
Cancer: Solid Tumors
Primary: Maximum Tolerable Dose (MTD) of E7080 Repeatedly Administered Twice a Day — 13 mg BID
Phase 3 N=264 Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.
Meningococcal Disease
Primary: Percentage of Subjects With Serum Bactericidal Antibody (SBA) Titers ≥1:4 Against Neisseria Meningitidis Serogroup B by Vaccine Group. — 26; 24; 98; 27 percentage of…
Phase 1 N=8 Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
Gastroesophageal Reflux Disease · Erosive Esophagitis · Heartburn
Primary: Time to In-Vivo Disintegration of Dexlansoprazole 30 mg Orally Disintegrating Tablets — 36.0 Seconds
Phase 2 N=17 Adverse Effects of RBC Transfusions: A Unifying Hypothesis
Healthy Volunteers
Primary: The Effects of Storage-related RBC Changes on Acetylcholine-stimulated (NO-mediated) Forearm Blood Flow. — 19.02; 18.42; 17.61; 22.89 mL / 100 mL / min
Phase 4 N=51 Quartet Lead and Resynchronization Therapy Options
Heart Failure
Primary: Number of Patients Whose Cardiac Output (CO) Value in Acute, as Measured Echocardiographically, Improves With the Different Stimulation Vectors Offered by the Quartet®…